TrialThe Lancet. Microbe2024

SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial.

Brittany L Ober Shepherd et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.